Key Drivers
- Liquidity Cushion
- Margin Recovery
- Weak Cash Conversion
AIAI Summary
IMCR now looks financially de-risked enough to support the stock, but the real investment question has shifted to execution: KIMMTRAK is durable, yet concentration in one franchise and negative cash flow mean the shares likely need second-asset pipeline data before a sustained re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Margin Recovery
- •Weak Cash Conversion
IMCR has a strong balance sheet and near-100% gross margins with improving Q1 2026 profitability, but negative cash flow, elevated costs, and a still-rich valuation limit the durability of the turnaround.
Price Behavior
Key Price Behavior Insights:
- •Lower-high pattern
- •Failed bounce
- •Near support
IMCR has been in a short-term downtrend over the last month, with lower highs/lower lows, support near $27.91-$28.00, and failed rebounds into $29.50-$30.00.
Rebounded from $27.91 to $30.73, then reversed back to $28.05
Sentiment & News
Key News Insights:
- •KIMMTRAK sales growth
- •Strong survival data
- •Robust cash balance
Immunocore reported solid Q1 growth, strong KIMMTRAK survival data, and a large cash position, reinforcing both near-term commercial momentum and financial flexibility.
The update is likely supportive for Immunocore by highlighting commercial traction, clinical credibility, and ample runway to fund growth
Similar Companies in Healthcare
Other companies in the same sector with AI ratings